CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03146650
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:21.662661+00:00
Published At: 2024-01-18T00:00:00+00:00
Record Updated At: 2024-01-18
Results Posted At: 2024-01-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Major Salivary Gland Carcinoma", "Minor Salivary Gland Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage IV Major Salivary Gland Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVC Major Salivary Gland Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-01-18"
protocolSection.identificationModule.nctId: "NCT03146650"
protocolSection.identificationModule.officialTitle: "Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-01-18"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.